Payment overview · 2025
General Payments
$7,829.68
97 reported records · 21 companies
Healthcare provider profile · identity verified
Jonathan Mt Chang, M.D.
Allopathic & Osteopathic Physicians|General Practice · BROOKLYN, NY · NPI 1114968385
Verified facts
What the public records show
CMS Open Payments records show Jonathan Mt Chang, M.D. received $7,829.68 in general payments during 2025 across 97 reported records.
Gilead Sciences, Inc. accounted for 62.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Nexletol, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Ubrelvy, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synjardy by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Nexletol by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ztlido by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $4,860.00 | 62.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $829.60 | 10.6% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $302.32 | 3.9% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $232.77 | 3.0% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $222.36 | 2.8% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $218.61 | 2.8% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $193.17 | 2.5% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $160.62 | 2.0% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $157.71 | 2.0% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $127.48 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $120.18 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.05 | 1.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.79 | 1.1% | 4 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.05 | 0.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.47 | 0.5% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $37.45 | 0.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.45 | 0.3% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.65 | 0.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.18 | 0.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.08 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.69 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,860.00 | 3 |
| Food and Beverage | $2,969.68 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $401.82 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $281.31 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $259.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $232.77 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $222.36 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $218.61 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $195.57 | 9 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $193.17 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $157.71 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $127.48 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $120.18 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $113.91 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $107.77 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $82.79 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $65.38 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $65.38 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $65.38 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $53.05 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $7.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 278 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 167 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 65 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 35 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 175 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
167 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
278 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
72 | 21 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
175 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 901 | 178 |
| Gabapentin | Gabapentin | 511 | 119 |
| Famotidine | Famotidine | 390 | 82 |
| Losartan Potassium | Losartan Potassium | 372 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 372 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 368 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 85 |
| Simvastatin | Simvastatin | 292 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 84 |
| Farxiga | Dapagliflozin Propanediol | 278 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 67 |
| Finasteride | Finasteride | 251 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 250 | 83 |
| Acarbose | Acarbose | 235 | 51 |
| Montelukast Sodium | Montelukast Sodium | 215 | 57 |
| Donepezil Hcl | Donepezil Hcl | 190 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 185 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 181 | 50 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 179 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 48 |
| Azithromycin | Azithromycin | 176 | 114 |
| Rybelsus | Semaglutide | 175 | 40 |
| Metformin Hcl Er | Metformin Hcl | 168 | 48 |
| Omeprazole | Omeprazole | 168 | 51 |
| Linzess | Linaclotide | 167 | 28 |
| Diclofenac Epolamine | Diclofenac Epolamine | 161 | 39 |
| Allopurinol | Allopurinol | 158 | 29 |
| Jardiance | Empagliflozin | 157 | 28 |
| Repaglinide | Repaglinide | 144 | 38 |
| Glipizide Er | Glipizide | 142 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 54 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 132 | 34 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 129 | 40 |
| Pregabalin | Pregabalin | 129 | 24 |
| Ezetimibe | Ezetimibe | 126 | 27 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 115 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 53 |
| Ammonium Lactate | Ammonium Lactate | 110 | 40 |
| Myrbetriq | Mirabegron | 110 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 22 |
| Colchicine | Colchicine | 103 | 23 |
| Fenofibrate | Fenofibrate | 102 | 21 |
| Alendronate Sodium | Alendronate Sodium | 99 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 22 |
| Nexium | Esomeprazole Magnesium | 97 | 22 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 96 | 45 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 96 | 18 |
| Januvia | Sitagliptin Phosphate | 94 | 19 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 91 | 15 |
| Vemlidy | Tenofovir Alafenamide | 85 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 83 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 83 | 21 |
| Metformin Hcl | Metformin Hcl | 83 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 83 | 16 |
| Ozempic | Semaglutide | 81 | 13 |
| Meloxicam | Meloxicam | 79 | 45 |
| Lidocaine | Lidocaine | 76 | 15 |
| Meclizine Hcl | Meclizine Hcl | 74 | 33 |
| Mometasone Furoate | Mometasone Furoate | 72 | 41 |
| Synjardy | Empagliflozin/Metformin Hcl | 72 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 71 | 14 |
| Azelastine Hcl | Azelastine Hcl | 70 | 40 |
| Restasis | Cyclosporine | 70 | 15 |
| Mupirocin | Mupirocin | 67 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 17 |
| Nexletol | Bempedoic Acid | 65 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 64 | 15 |
| Glimepiride | Glimepiride | 61 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 61 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 11 |
| Lorazepam | Lorazepam | 55 | 27 |
| Nifedipine Er | Nifedipine | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | 12 |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 40 |
| Furosemide | Furosemide | 47 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 43 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 17 |
| Procto-Med Hc | Hydrocortisone | 39 | 13 |
| Alcohol Swab | Alcohol Antiseptic Pads | 38 | 18 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 37 | 23 |
| Hydrocortisone | Hydrocortisone | 36 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | 12 |
| Prolia | Denosumab | 35 | 25 |
| Telmisartan | Telmisartan | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 25 |
| Atenolol | Atenolol | 32 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 31 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 21 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Ztlido | Lidocaine | 29 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 12 |
| Naproxen | Naproxen | 26 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | 20 |
| Ubrelvy | Ubrogepant | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | 16 |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | 11 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Folic Acid | Folic Acid | 19 | suppressed |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | 13 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Entecavir | Entecavir | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Evista | Raloxifene Hcl | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,829.68 · 97 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, BREZTRI, Brinsupri, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GEMTESA, IBSRELA, JARDIANCE, LINZESS, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PYRUKYND, QULIPTA, REPATHA, REXULTI, REZDIFFRA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VYALEV, ZORYVE, ZTLido | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error